USA – Data Integrity for In Vivo Bioavailability and Bioequivalence Studies: Guidance for Industry
The purpose of this guidance is to provide recommendations to applicants and testing site
management on achieving and maintaining data integrity for the clinical and...
USA – Center for Drug Evaluation and Research – Office of Pharmaceutical Quality :...
FDA’s Office of Office of Pharmaceutical Quality (OPQ) published its 2023 Annual Report, which details the many ways OPQ assures the availability, safety, and...
USA – Study: Few FDA-approved targeted cancer drugs meet ESMO benefit benchmarks
Fewer than one-third of molecularly targeted cancer drugs recently approved by the US Food and Drug Administration (FDA) meet established European benchmarks for clinical...
USA – FDA turns attention to data integrity lapses at testing sites in new...
The US Food and Drug Administration (FDA) has issued a draft guidance outlining how manufacturers can ensure the data integrity of bioavailability (BA) and...
USA – FDA finalizes guidance on electronic submission of BA/BE adverse event reports to...
The US Food and Drug Administration (FDA) has finalized guidance that spells out how generic drug manufacturers can electronically submit expedited individual case safety...
USA – FDA Approves New Antibiotic for Three Different Uses
Today, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections...
USA – FDA shifts IND safety reporting over to FAERS in finalized guidance
The US Food and Drug Administration (FDA) has finalized guidance specifying that after 1 April 2026, sponsors will have to submit investigational new drug...
USA – FDA launches new Quantitative Medicine Center of Excellence
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has announced the establishment of a new quantitative medicine (QM)...
USA – FDA reduces number of samples to retain for BA/BE testing
In a part-draft, part-final guidance issued on Tuesday, the US Food and Drug Administration (FDA) finalized its policy on the quantity of reserve samples...
USA – FDA offers guidance on observational studies as RWE
The US Food and Drug Administration (FDA) this week issued new draft guidance on study design and analysis for non-interventional studies being included as...
